Does persistently low ferritin during oral iron therapy indicate ongoing loss or poor absorption?

When oral iron supplementation fails to increase ferritin levels, it typically signals a breakdown in the iron balance equation: either the rate of loss is too high, or the rate of absorption is too low.

Clinical and mechanistic evidence

Persistently low ferritin despite treatment—often termed refractory iron deficiency—is a critical clinical signal. In patients who take oral iron as prescribed, a failure to raise ferritin by at least 1–2 mg/dL per week usually indicates one of two primary issues:

• Ongoing iron loss: In premenopausal women, heavy menstrual bleeding (menorrhagia) is the most common cause of iron loss exceeding the capacity of oral therapy. However, occult gastrointestinal (GI) bleeding is a significant concern across all demographics. Research indicates that 8% to 15% of patients with refractory iron deficiency are eventually diagnosed with a GI malignancy, making thorough diagnostic investigation (such as endoscopy) essential when ferritin remains low.
• Impaired GI absorption: For iron to be stored as ferritin, it must be solubilized by gastric acid and transported across the duodenal mucosa. This process is frequently interrupted by:
  • Celiac Disease: Villous atrophy in the duodenum directly reduces the surface area available for iron uptake.
  • Hypochlorhydria: Conditions like atrophic gastritis or the use of proton pump inhibitors (PPIs) reduce stomach acid, preventing iron from reaching the soluble form required for absorption.
  • H. pylori Infection: This bacterium not only causes inflammation but may compete for iron and raise gastric pH, significantly blunting oral iron efficacy.
• Hepcidin-mediated block: Hepcidin is the body's master iron regulator. In the presence of inflammation or even from the oral iron itself, hepcidin levels rise and trigger the degradation of ferroportin (the only known cellular iron exporter). This "locks" iron inside intestinal cells, preventing it from reaching the bloodstream and being stored as ferritin.

Clinical implications

When oral iron fails, increasing the dose is rarely the solution and may worsen GI side effects. Clinical guidelines suggest that if ferritin does not respond after 4–6 weeks of therapy, the next steps include:

• Diagnostic screening for celiac disease and H. pylori.
• Investigating occult blood loss via gynecological or GI evaluation.
• Transitioning to Intravenous (IV) Iron, which bypasses the absorption barriers of the GI tract and the hepcidin-mediated sequestration in enterocytes, directly replenishing ferritin stores.

Bottom line

Persistently low ferritin during oral supplementation is highly suggestive of ongoing blood loss (often occult) or an underlying malabsorptive disorder such as celiac disease or H. pylori infection. Because oral iron cannot overcome these physiological barriers, its failure is a diagnostic indicator that necessitates further medical investigation and often a transition to intravenous iron therapy.